Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Asper Biotech's Hutterite Genetic Diseases Test

Premium

Asper Biotech recently launched a new carrier test to detect the most common mutations associated with autosomal recessive disorders that are overrepresented in the Hutterite population.

Hutterites are a communal branch of Anabaptists who, like the Amish and Mennonites, trace their roots to the Radical Reformation of the 16th century. Today, about 42,000 Hutterites live in communities in western parts of the US and Canada.

Asper's Hutterite Genetic Diseases Test detects mutations associated with conditions and diseases commonly found in Hutterite populations, including alveolar capillary dysplasia with limb deficiency, arrhythmogenic cardiomyopathy, Bardet-Biedl syndrome, and cystic fibrosis. In total, the test covers 35 mutations in 32 genes.

Tartu, Estonia-based Asper relies on its arrayed primer extension-based genotyping technology to carry out its service. The company said on its website that a standard service with a turnaround time of between four and six weeks costs €245 ($330). Its express service, where results are delivered within seven working days, costs €290.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.